We previously identified a series of triazolopyrimidines with antitubercular activity (1). Compounds were bacteriostatic for replicating *Mycobacterium tuberculosis* but bactericidal for nonreplicating bacteria. We explored the structure-activity relationship and determined druglike properties. We wanted to determine the target and/or mechanism of action of the piperacillin-tazobactam (TZP) series. Since previous work in our group and others had identified several common targets, we tested a set of analogs for activity against strains carrying mutations in promiscuous targets (Fig. 1) (2).

We selected DprE1, MmpL3, and QcrB as the most common targets (3–6). We determined activity against strains carrying either DprE1C387S, MmpL3F255L, or QcrBA396T mutations in the parental strain *M. tuberculosis* H37Rv-LP (ATCC 25618) (Table 1) (7). MICs were determined as described after 5 days of growth in Middlebrook 7H9 medium plus 10% (vol/vol) oleic acid-albumin-dextrose-catalase (OADC) supplement and 0.05% (wt/vol) Tween 80 and were determined using a 10-point, 2-fold serial dilution series of each compound (8). We saw a small shift in MICs in the QcrBA396T mutant strain, namely, an ~2- to 4-fold increase in resistance. No significant changes were seen in the DprE1C387S or MmpL3F255L mutant strains.

In order to confirm that the QcrB mutation did lead to resistance and is the likely target, we tested compounds against two additional strains carrying QcrB mutations (T313I and M342T) (5, 9). We determined MICs after 5 days of growth in Middlebrook 7H9 medium plus 10% (vol/vol) OADC supplement and 0.05% (wt/vol) Tween 80 and were determined using a 10-point, 2-fold serial dilution series of each compound (8). We saw a small shift in MICs in the QcrB313I mutant strain, namely, an ~2- to 4-fold increase in resistance. No significant changes were seen in the DprE1C387S or MmpL3F255L mutant strains.

We confirmed high-level resistance in both strains.

QcrB is a component of the *cytochrome bc* complex in the electron transport chain; *M. tuberculosis* strains in which the alternative cytochrome oxidase (*cytochrome bd*) is deleted are hypersusceptible to QcrB inhibitors (10, 11). We also tested three compounds against *M. tuberculosis* H37Rv ATCC 272942 and the isogenic *CycD* deletion strain (11). As expected, *M. tuberculosis* H37Rv ATCC 27294 was more resistant to the compounds than H37Rv ATCC 25618, as has been noted with other QcrB inhibitors, although the mechanism behind this is unknown (10–12). Deletion of cytochrome *bd*
activity resulted in higher sensitivity to the three compounds (Table 2). Taken together, these data strongly support the hypothesis that the target of the series is QcrB.

We have previously demonstrated that QcrB inhibitors lead to the depletion of intracellular ATP that is independent of the inhibition of growth and is consistent with disruption of the electron transport chain. We determined the effect of compounds on ATP levels (Fig. 2). *M. tuberculosis* was exposed to compounds for 24 h; ATP levels were measured using the BacTiter-Glo assay kit (Promega). Growth was measured by the optical density at 590 nm (OD590). Q203 caused depletion of ATP levels at concentrations lower than the MIC (Fig. 2F). Similarly, ATP levels were reduced in a dose-dependent fashion on exposure to TZP molecules at concentrations which did not inhibit growth (Fig. 2A to D). Depletion of ATP was not seen with the protein synthesis inhibitor kanamycin (Fig. 2E). These data further support the disruption of the electron transport chain as the mechanism of action of the TZP series.

We wanted to determine if there were additional targets or mechanism(s) of resistance, so we isolated and characterized mutants resistant to the series. We selected compounds from our original set with the lowest liquid MIC and determined the MIC against *M. tuberculosis* H37Rv ATCC 25618 on solid medium (Table 3). We selected two

### TABLE 1 Activity against strains of *M. tuberculosis*

| Molecule   | MICa (µM) of: | DprE1 C387S | MmpL3 F255L | QcrB A396T |
|------------|---------------|-------------|-------------|------------|
|            | Parental (n)  |             |             |            |
| TPN-0006218| 2.6 ± 1.3 (9) | 0.94 ± 0.67 | 2 ± 0.99    | 6.8 ± 2.8  |
| TPN-0006239| 1.1 ± 0.5 (10)| 0.42 ± 0.07 | 0.86 ± 0.21 | 3.4 ± 0.28 |
| TPN-0006243| 3.7 ± 2.9 (14)| 0.95 ± 0.29 | 2.7 ± 2.4   | 5.7 ± 2.1  |
| TPN-0006245| 2 ± 1.1 (11)  | 0.92 ± 0.3  | 2 ± 0.07    | 5.6 ± 2.5  |
| TPN-0006267| 1.4 ± 1.4 (8) | 0.66 ± 0.01 | 1.8 ± 0.57  | 5.9 ± 3.5  |

*MICs were determined after 5 days in two independent experiments (except for parental where n is the number of independent biological replicates). The genotype of the strain is noted. The parental strain is *M. tuberculosis* H37Rv-LP (ATCC 25618).*

FIG 1 Structures of molecules.
compounds and plated ~10^8 bacteria onto 5× and 10× solid MIC as described (4). We isolated colonies and confirmed resistant mutants by measuring the MIC on solid medium; we obtained nine resistant isolates for TPN-0006239 and five resistant isolates for TPN-0006267 (Table 3).

We sequenced the entire QcrB gene in all 14 isolates, but none of them had mutations (Table 3). We had previously seen mutations in Rv1339 leading to resistance to other QcrB inhibitors (5, 9), so we sequenced Rv1339. We found the same mutation in 11 strains (P121L); 1 strain had the mutation S120P (Table 3). Two strains had no mutations in Rv1339. We have previously linked Rv1339 mutations to resistance to other QcrB inhibitor series, namely, the imidazopyridines and the phenoxyalkylimidazoles (5, 9). Recent work in the related organism Mycobacterium smegmatis suggests that Rv1339 is an atypical class II cAMP phosphodiesterase that has been linked to antibiotic tolerance (13). In addition, a P94L mutation in Rv1399 led to increased persistence in animal models and increased resistance to external stress in Mycobacterium canetti, which was proposed to be due to changes in cell wall permeability (14). It is possible that the mutations we obtained lead to decreased compound permeation leading to resistance. However, it is unusual that resistance is seen largely with QcrB inhibitors, not as a general phenomenon; an alternative explanation for resistance could be changes in the intracellular ATP pool due to decreased turnover of cAMP.

We had demonstrated previously that this series had bacteriostatic activity against replicating M. tuberculosis but bactericidal activity against nonreplicating bacteria (1). We have noted this biological activity profile for other QcrB inhibitors, and thus, it is

| Molecule | QcrB_{H37Rv} | QcrB_{cydKO} | Parental | cydKO |
|----------|---------------|---------------|----------|------|
| TPN-0006239 | >20 | >20 | 5.9 ± 0.6 | 0.38 ± 0.04 |
| TPN-0006243 | >20 | 11 | 9.5 ± 3.5 | 0.13 ± 0.007 |
| TPN-0006245 | >20 | >20 | 2.2 ± 0.9 | <0.39 |
| TPN-0006267 | >20 | 10 | nd | nd |

* MICs were determined after 5 days. The genotype of the strain and parental strain is noted. nd, not determined.

**TABLE 2 Activity against strains of M. tuberculosis**

**FIG 2** T2P molecules lead to the depletion of intracellular ATP levels. ATP levels were measured in M. tuberculosis using the BacTiter Glo assay kit; growth was measured by OD_{590}. Data were normalized to the untreated control (dimethyl sulfoxide [DMSO] only).
consistent with it being an inhibitor of aerobic respiration (5, 9, 12). Since other QcrB inhibitors are active against intracellular bacteria, we tested the TZP series for activity against *M. tuberculosis* in human THP-1 macrophages. Macrophages were infected with *M. tuberculosis* expressing luciferase (15) at a multiplicity of infection of 1 for 24 h, washed to remove extracellular bacteria, and then exposed to the compound for 72 h. Bacterial growth was measured by fluorescence. We tested five representative molecules, and all had potent activity with an 50% inhibitory concentration (IC50) of 1 μM (Table 4).

Since we identified the target of the TZP series as aerobic respiration, we determined whether the series might also inhibit mitochondrial respiration. We determined cytotoxicity against HepG2 cells cultured in Dulbecco’s modified Eagle’s medium (DMEM) with galactose as the carbon source to force the cells into using mitochondrial respiration (16). HepG2 cells were exposed to the compound for 72 h, and viability was measured using CellTiterGlo (Promega) (1). Of eight compounds, six showed some cytotoxicity, and all had potent activity with an 50% inhibitory concentration (IC50) of <1 μM (Table 4).

Since we identified the target of the TZP series as aerobic respiration, we determined whether the series might also inhibit mitochondrial respiration. We determined cytotoxicity against HepG2 cells cultured in Dulbecco’s modified Eagle’s medium (DMEM) with galactose as the carbon source to force the cells into using mitochondrial respiration (16). HepG2 cells were exposed to the compound for 72 h, and viability was measured using CellTiterGlo (Promega) (1). Of eight compounds, six showed some cytotoxicity (Table 5), although they still had a good selectivity index (activity was more potent against *M. tuberculosis*). We compared the IC50s under this condition to those generated when HepG2 cells were cultured in glucose when mitochondrial respiration is not active (1). There was less than a 2-fold difference in the cytotoxicity, confirming that molecules are not inhibiting eukaryotic respiration.

In conclusion, we have determined that the most likely target of the triazolopyrimidine series in *M. tuberculosis* is QcrB, a component of the electron transport chain. We demonstrated that mutations in either the target QcrB or the putative phosphodiesterase Rv1339 lead to resistance. This information adds another series of interest to the list of known or proposed QcrB inhibitors, which include the imidazopyridine amides

### Table 3: Characterization of resistant isolates of *M. tuberculosis*

| Strain       | Compound     | MICa (μM) | Genotype of: | Rv1339 | QcrB |
|--------------|--------------|-----------|--------------|--------|------|
| H37Rv-LP     | TPN-0006239  | 1.6       | wt           | wt     | wt   |
| LP-0497553-RM1 | TPN-0006239 | 25        | P121L        | wt     | wt   |
| LP-0497553-RM2 | TPN-0006239 | 25        | P121L        | wt     | wt   |
| LP-0497553-RM4 | TPN-0006239 | 50        | P121L        | wt     | wt   |
| LP-0497553-RM5 | TPN-0006239 | 50        | P121L        | wt     | wt   |
| LP-0497553-RM10 | TPN-0006239 | 50        | S120P        | wt     | wt   |
| LP-0497553-RM11 | TPN-0006239 | 50        | P121L        | wt     | wt   |
| LP-0497553-RM14 | TPN-0006239 | 50        | wt           | wt     | wt   |
| LP-0497553-RM15 | TPN-0006239 | 50        | P121L        | wt     | wt   |
| LP-0497553-RM23 | TPN-0006239 | 50        | wt           | wt     | wt   |
| H37Rv-LP     | TPN-0006267  | 1.6       | wt           | wt     | wt   |
| LP-0499227-RM1 | TPN-0006267 | >100      | P121L        | wt     | wt   |
| LP-0499227-RM2 | TPN-0006267 | >100      | P121L        | wt     | wt   |
| LP-0499227-RM3 | TPN-0006267 | >100      | P121L        | wt     | wt   |
| LP-0499227-RM4 | TPN-0006267 | 25        | P121L        | wt     | wt   |
| LP-0499227-RM7 | TPN-0006267 | >100      | P121L        | wt     | wt   |

*MICs were determined in 24-well agar plates after 3 weeks of incubation. Two genes (qcrB and rv1339) were sequenced in all strains.

wt, wild type.

### Table 4: Activity against intracellular *M. tuberculosis*

| Molecule     | Intracellular IC50a |
|--------------|---------------------|
| TPN-0006218  | 0.23 ± 0.08         |
| TPN-0006267  | 0.21 ± 0.11         |
| TPN-0006273  | 0.19 ± 0.13         |
| TPN-0006288  | 0.076 ± 0.032       |
| TPN-0006290  | 0.18 ± 0.09         |

*IC50s were measured after 72 h in THP-1 cells infected at a multiplicity of infection of 1 (n = 2).*
TABLE 5 Cytotoxicity against human HepG2 cellsa

| Molecule   | IC50b (μM) | Glucose | Galactose |
|------------|------------|---------|-----------|
| TPN-0006218| >100       | 65      |           |
| TPN-0006239| >100       | 73      |           |
| TPN-0006243| >100       | >100    |           |
| TPN-0006245| 58         | 39      |           |
| TPN-0006267| >100       | >100    |           |
| TPN-0006273| 100        | 76      |           |
| TPN-0006288| 44         | 23      |           |
| TPN-0006290| 49         | 33      |           |

aHepG2 cells were cultured in medium containing either galactose or glucose as the carbon source.
bIC50, the concentration required to reduce cell number by 50%, was determined after 3 days of exposure to compounds.

(9), Q203 (17), lansoprazole (18), phenoxylalkylimidazoles (5), morpholino thiophenes (6), quinolinyl acetamides (19), pyrazolopyridines (20), and arylvinylpiperazine amides (21). Since QcrB is a clinically validated target (22), this series is an attractive one to develop further.

ACKNOWLEDGMENTS

We thank Lena Anoshchenko, Junitta Guzman, David Roberts, Dean Thompson, and James Vela for technical assistance.

This research was supported with funding from the Bill and Melinda Gates Foundation, under grant OPP1024038 and INV-005585.

REFERENCES

1. Zuniga ES, Korkegian A, Mullen S, Hembre EJ, Ornstein PL, Cortez G, Biswas K, Kumar N, Cramer J, Masquelin T, Hipksind PA, Odingo J, Parish T. 2017. The synthesis and evaluation of triazolopyrimidines as anti-tubercular agents. Bioorg Med Chem 25:3922–3946. https://doi.org/10.1016/j.bmc.2017.05.030.
2. Goldman RC. 2013. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis? Tuberculosis (Edinb) 93:569–588. https://doi.org/10.1016/j.tube.2013.09.003.
3. McNeil MB, O'Malley T, Dennison D, Shelton CD, Sunde B, Parish T. 2020. Multiple mutations in Mycobacterium tuberculosis MmpL3 increase resistance to MmpL3 inhibitors. mSphere 5:e00985-20. https://doi.org/10.1128/mSphere.00985-20.
4. Joerger TR, O'Malley T, Liao R, Guinn KM, Hickey MJ, Mohaideen N, Murphy KC, Boshoff HM, Mizrahi V, Rubin EJ, Sassetti CM, Barry CE, Sherman DR, Parish T, Sacchettini JC. 2013. Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS One 8:e75245. https://doi.org/10.1371/journal.pone.0075245.
5. Chandrasekera NS, Berube BJ, Shetty G, Chettiar S, O'Malley T, Manning A, Flint L, Awaathi D, Joerger TR, Sacchettini J, Masquelin T, Hipksind PA, Odingo J, Parish T. 2017. Improved phenoxylalkylimidazoles with activity against Mycobacterium tuberculosis appear to target QcrB. ACS Infect Dis 3:989–916. https://doi.org/10.1021/acsinfectdis.7b00112.
6. Cleghorn LAT, Ray PC, Odingo J, Kumar A, Wescott H, Korkegian A, Masquelin T, Lopez Moure A, Wilson C, Davis S, Huggett M, Turner P, Smith A, Epemolu O, Zuccotto F, Riley J, Shishikura Y, Ferguson L, Rullas J, Guijarro L, Turner P, Smith A, Epemolu O, Zuccotto F, Riley J, Shishikura Y, Ferguson L, Rullas J, Guijarro L, Read AJC, Mizrahi V, Warner DF. 2017. Susceptibility of Mycobacterium tuberculosis cytochrome bd oxidase mutants to compounds targeting the terminal respiratory oxidase, cytochrome c. Antimicrob Agents Chemother 62:e02439-17. https://doi.org/10.1128/AAC.02439-17.
7. Ioerger TR, Feng Y, Ganesula K, Chen X, Dobos KM, Fortune S, Jacobs WR, Mizrahi V, Parish T, Rubin E, Sassetti C, Sacchettini JC. 2010. Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories. J Bacteriol 192:3645–3653. https://doi.org/10.1128/JB.00166-10.
8. Ollinger J, Bailey MA, Morasck GC, Casey A, Florio S, Alling T, Miller MJ, Parish T. 2013. A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis. PLoS One 8:e60531. https://doi.org/10.1371/journal.pone.0060531.
9. O’Malley T, Alling T, Early JV, Wescott HA, Kumar A, Moraski GC, Miller MJ, Masquelin T, Hipksind PA, Parish T. 2018. Imidazopyridine compounds inhibit mycobacterial growth by depleting ATP levels. Antimicrob Agents Chemother 62:e02439-17. https://doi.org/10.1128/AAC.02439-17.
10. Moosa A, Lamprecht DA, Arora K, Barry CE, Boshoff HM, Joerger TR, Steyn AJC, Mizrahi V, Warner DF. 2017. Susceptibility of Mycobacterium tuberculosis cytochrome c oxidase mutants to compounds targeting the terminal respiratory oxidase, cytochrome c. Antimicrob Agents Chemother 61:e1338-17. https://doi.org/10.1128/AAC.01338-17.
11. Arora K, Ochoa-Montaño B, Tsang PS, Blundell TL, Davies SS, Mizrahi V, Bayliss T, Mackenzie CJ, Cleghorn LAT, Ray PC, Wyatt PG, Uh E, Lee J, Barry CE, Boshoff Hl. 2014. Respiratory flexibility in response to inhibition of cytochrome c oxidase in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:6962–6965. https://doi.org/10.1128/AAC.03486-14.
12. Berube BJ, Parish T. 2018. Combinations of respiratory chain inhibitors have enhanced bactericidal activity against Mycobacterium tuberculosis. Antimicrob Agents Chemother 62:e01677-17. https://doi.org/10.1128/AAC.01677-17.
13. Thomson M, Nunta K, Cheyne A, Liu Y, Garza-Garcia A, Larrouy-Maumus G. 2020. Modulation of the cAMP levels with a conserved actinobacteria phosphodiesterase enzyme reduces antimicrobial tolerance in mycobacteria [Internet]. bioRxiv. https://doi.org/10.1101/2020.08.26.267864.
14. Allen AC, Malaga W, Gaudin C, Volle A, Moreau F, Hassan A, Astarie-Dequeker C, Peixoto A, Antoine R, Pawlik A, Frigui W, Berrone C, Brons R, Supply P, Guilhot C. 2021. Parallel in vivo experimental evolution reveals that increased stress resistance was key for the emergence of persistent tuberculosis bacilli. Nat Microbiol 6:1082–1093. https://doi.org/10.1038/s41564-021-00938-4.
15. Andreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, Ripoll J, Parish T, Bancroft GJ, Schalib U, Robertson BD, Wales S. 2010. Optimisation of bioluminescent reporters for use with mycobacteria. PLoS One 5:e10772. https://doi.org/10.1371/journal.pone.0010777.
16. Orlicka-Płocka M, Gurdara-Wozna D, Fedoruk-Wyszomirska A, Wyszko E. 2020. Circumventing the Crabtree effect: forcing oxidative phosphorylation (OXPHOS) via galactose medium increases sensitivity of HepG2 cells.
to the purine derivative kinetin riboside. Apoptosis 25:835–852. https://doi.org/10.1007/s10495-020-01637-x.

17. Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, Jiricek J, Jung J, Jeon HK, Cechetto J, Christophe T, Lee H, Kempf M, Jackson M, Lenaerts AJ, Pham H, Jones V, Seo MJ, Kim YM, Seo M, Seo JJ, Park D, Ko Y, Choi I, Kim R, Kim SY, Lim SB, Yim S-A, Nam J, Kang H, Kwon H, Oh C-T, Cho Y, Jang Y, Kim J, Chua A, Tan BH, Nanjundappa MB, Rao SPS, Barnes WS, Wintjens R, Walker JR, Alonso S, Lee S, Kim J, Oh S, Oh T, Nehrbass U, Han S-J, No Z, et al. 2013. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med 19:1157–1160. https://doi.org/10.1038/nm.3262.

18. Rybniker J, Vocat A, Sala C, Busso P, Pojer F, Benjak A, Cole ST. 2015. Lansoprazole is an antituberculous prodrug targeting cytochrome bc1. Nat Commun 6:7659. https://doi.org/10.1038/ncomms8659.

19. Phummarin N, Boshoff H, Tsang PS, Dalton J, Wiles S, Barry RD CE, Copp BR. 2016. SAR and identification of 2-(quinolin-4-yloxy)acetamides as Mycobacterium tuberculosis cytochrome bc1 inhibitors. MedChemComm 7:2122–2127. https://doi.org/10.1039/c6md00236f.

20. Lu X, Williams Z, Hards K, Tang J, Cheung C-Y, Aung HL, Wang B, Liu Z, Hu X, Lenaerts A, Woolfiser L, Hastings C, Zhang X, Wang Z, Rhee K, Ding K, Zhang T, Cook GM. 2019. Pyrazolopyridine inhibitor of the respiratory cytochrome bcc complex for the treatment of drug-resistant tuberculosis. ACS Infect Dis 5:239–249. https://doi.org/10.1021/acscinfectdis.8b00225.

21. Foo CS, Lupien A, Kienle M, Vocat A, Benjak A, Sommer R, Lamprecht DA, Steyn AJC, Pethe K, Piton J, Altmann K-H, Cole ST. 2018. Arylvinylpyperazine amides, a new class of potent inhibitors targeting QcrB of Mycobacterium tuberculosis. mBio 9:e01276-18. https://doi.org/10.1128/mBio.01276-18.

22. de Jager VR, Dawson R, van Niekerk C, Hutchings J, Kim J, Vanker N, van der Merwe L, Choi J, Nam K, Diacon AH. 2020. Telacebec (Q203), a new antituberculosis agent. N Engl J Med 382:1280–1281. https://doi.org/10.1056/NEJMoa1913327.